Variable Thiamine Treatment Placebo
  Baseline Therapy Washout Baseline Therapy Washout
Plasma thiamine (nM/l) 10.6 (0.8–84.5) 98.2 (2.6–294.5) c, f 10.9 (3.6–22.7) i 7.1 (1.1–31.3) 7.1 (2.4–16.6) 9.1 (4.2–16.3)
 Urinary thiamine (µmol/24 h) 1.63 (0.45–7.66) 47.69 (0.40–182.79) c,f 1.42 (0.10–9.72) i 1.53 (0.67–4.46) 1.71 (0.15–9.73) 1.16 (0.00–5.44)
Urinary albumin Excretion   (mg/24 h)(30-300 MAU) 43.7 (33.0–120.9) 30.1 (12.0–38.2)b,f 20.9 (7.0–35.0)f,h 50.9 (33–122) 35.5 (6.4–82.0) 30 (3.5–80.4)f
Thiamine clearance(ml/min) 112 (8-819) 273(3-789)d 92(18-237)h 189(26-955) 149 (12-663) 102(12-334)e
Plasma glucose (mg/dl)(>126) 181.8±57.6 181.8±70.2 144±6.3d 177.58±55.8 158.4±43.24 144±55.8d
Glycated HbAic% (>7 diabetes) 9.2±1.3 9.0±1.8 7.8±1.6  e,h 8.8±1.8 8.5±1.7 8.4±1.7
Total cholesterol (mg/dl) 200- 299)(high) 203.40±50.27 188.32 (100.15- 374.90) 178.26 (127.22–278.42) 185.22±40.98 171.30±64.19 215.39±76.7h
LDL-cholesterol (mg/dl)  (130-159(borderline high) 106.34±47.14 98.996±66.12 93.19±32.09a 106.34±35.96 92.05±460.01 123.35±47.95g
VLDL(mg/dl)( 40-100(high) 46.330±31.792 55.62±36.46b 48.260± 30.62 31.30 ±16.339 36.425±17.24d 38.760 ± 13.9 e
HDL-cholesterol (mg/dl)(F<50,M<40)increased risk of coronary artery disease 49.88±13.53 41.76±14.30d 44.47±9.28 47.95±10.44 37.50±8.89f 52.97±21.65h
Triacylglycerol (mg/dl) (200-499 high), 198.47 (53.4- 739.59) 202.03 (81.66- 620.73) 231.4(79.21- 736.03) 134.39(72.98- 377.3) 159.31 (56.07- 357.78)d 175.33 (96.12- 396.94)d
BILIRUBIN(0.1-1mg/dl) 0.550±0.244 0.470±0.194 e 0.503±0.24 0.514±0.283 0.382±0.185g  
ALP(U/L)20-160 103.30±33.48 102.85±33.25 91.10±24. 83 88.20±29.84 80.65±44.75 84.1±34.15
ALT(U/L)30-65 360.05±10.49 31.15± 10.36 32.10±10.59 36.10±10.40 31.85±11.41 36.20±15.81
AST(U/L)15-37 22.60±9.70 19.00 ± 7.21 22.15±9.36 21.65±7.70 15.95±8.80 d 20.55±5.68
Table 2: The Thiamine, metabolic and liver function profile before and after three month thiamine treatment and after two month washout period.